The Saudi Food & Drug Authority (SFDA) has recently released MDS-G27, a new regulatory guidance for Digital Health Products, marking a significant shift in how digital health solutions are classified, assessed, and regulated in the Kingdom of Saudi Arabia.
This guidance is a crucial development for digital health innovators, software developers, medical device manufacturers, and healthcare technology companies looking to enter or expand in the Saudi market.
Understanding MDS-G27: A Regulatory Milestone
MDS-G27 provides long-awaited clarity on the regulatory treatment of digital health technologies—ranging from mobile health (mHealth) applications to AI-driven clinical decision support systems. With Saudi Arabia rapidly advancing its healthcare digitalization under Vision 2030, this guidance ensures innovation progresses alongside patient safety and regulatory compliance.
Key Highlights of SFDA MDS-G27
- Clear Distinction Between Medical and Wellness Products
- Risk-Based Regulatory Framework
- Defined Classification Criteria
- Balanced Compliance & Innovation
1. Clear Distinction Between Medical and Wellness Products
The guidance clearly defines regulatory boundaries between:
- SFDA-regulated medical devices, and
- Non-regulated wellness or lifestyle applications
This helps companies determine early whether their product falls under SFDA oversight, reducing uncertainty and regulatory risk.
2. Risk-Based Regulatory Framework
MDS-G27 introduces a risk-based classification approach for digital health technologies, covering:
- Mobile health (mHealth) apps
- Software as a Medical Device (SaMD)
- AI/ML-enabled clinical tools
Higher-risk products face stricter regulatory controls, while lower-risk solutions benefit from proportionate oversight.
3. Defined Classification Criteria
The guidance sets out clear criteria based on:
- Intended medical purpose
- Interaction with patient health data
- Clinical decision-making impact
This enables developers to accurately assess whether their product requires SFDA registration, listing, or approval.
4. Balanced Compliance & Innovation
SFDA ensures that compliance requirements align with patient safety and product performance, while still encouraging innovation in digital health and AI technologies.
Why MDS-G27 Matters for Digital Health Companies
Saudi Arabia is actively bridging innovation with regulatory clarity. MDS-G27 empowers developers and manufacturers to bring digital health solutions to market with confidence and transparency, avoiding regulatory ambiguity.
Importantly, even software-only products may now fall under regulatory scrutiny if they:
- Interact with health or patient data
- Influence diagnosis, monitoring, or treatment decisions
This represents a major shift for tech-driven healthcare companies previously operating outside traditional medical device regulations.
How RIAR Consulting Can Support You
Navigating SFDA’s evolving digital health regulations requires expert regulatory strategy and early planning. At RIAR Consulting, we help companies:
- Determine product classification under MDS-G27
- Develop compliant digital health regulatory strategies
- Manage SFDA registration and submissions
- Align innovation roadmaps with Saudi regulatory expectations
Final Thoughts
SFDA’s MDS-G27 is more than a guidance—it is a strategic framework shaping the future of digital health regulation in Saudi Arabia. Companies that understand and adapt early will gain a strong competitive advantage in one of the Middle East’s fastest-growing healthcare markets.
Need a quick breakdown of how MDS-G27 impacts your digital health product strategy? RIAR Consulting is here to guide you—reach out to our regulatory experts today.
What readers think
No ratings yet
No comments yet. Be the first to share your view.